Dr. Sabari on Future of Immunotherapy in SCLC

Joshua Sabari, MD
Published: Friday, Mar 03, 2017



Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the future that immunotherapy has in the field of small cell lung cancer (SCLC).

The biomarker story regarding immunotherapy is still playing out in SCLC, Sabari explains. Ongoing research will determine what role this type of treatment will actually have. What is interesting about data with immunotherapy, he adds, is that responses to such treatment is not correlated with PD-1/PD-L1 expression. This is something that needs to be further studied and clarified because it complicates the development and design of clinical trials.

Sabari hopes that immunotherapy does end up having positive outcomes in this patient population so that it provides another tool in the armamentarium. However, there needs to be more understanding of the activity in the disease.
SELECTED
LANGUAGE


Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the future that immunotherapy has in the field of small cell lung cancer (SCLC).

The biomarker story regarding immunotherapy is still playing out in SCLC, Sabari explains. Ongoing research will determine what role this type of treatment will actually have. What is interesting about data with immunotherapy, he adds, is that responses to such treatment is not correlated with PD-1/PD-L1 expression. This is something that needs to be further studied and clarified because it complicates the development and design of clinical trials.

Sabari hopes that immunotherapy does end up having positive outcomes in this patient population so that it provides another tool in the armamentarium. However, there needs to be more understanding of the activity in the disease.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x